meglitinide
Enable an agent to identify the meglitinide drug class and its members, explain their shared pharmacological role and distinguish class-level information from evidence about individual medicines.
Bundle → Layer → Finding → Questions Filled
5 bundles · 9 layers · 12 findings · 20 questions
Meglitinide referent and identity Resolve the ambiguous name and establish the molecular identity owned by this registry entry.
Registry referent
Determine what the originating registry record actually denotes.
Compound or class
The draft treats the individual compound as a provisional referent; the missing registry definition leaves that interpretation unsettled.
- Does the originating registry identifier denote the individual molecule or the meglitinide drug class? boundary
- Which source record, definition, and identifier relationships establish that interpretation? provenance
Molecular reference
Anchor the compound interpretation in structure and consistent identifiers.
Verified meglitinide structure
PubChem lists an individual meglitinide compound as CID 41214 with formula C17H16ClNO4; this is a candidate reference, not proof of the registry's intended referent. Source: [PubChem Meglitinide](https://pubchem.ncbi.nlm.nih.gov/compound/Meglitinide).
- Which canonical structure and InChIKey identify the intended meglitinide compound? definition
- Which CAS and EC identifiers can be verified against that same structure rather than against a class or related drug? provenance
Meglitinide material fitness Assess whether a physical sample contains the intended compound in a characterized, usable state.
Form and composition
Record the actual chemical form and analytically supported composition.
Sample identity and content
Require sample-specific identity and content evidence before attributing an observation to meglitinide.
- Is the sample the parent compound, a specified salt or solvate, or a mixture containing meglitinide? boundary
- Which identity tests and quantitative methods establish meglitinide content, residual solvents, and relevant impurities? measurement
Physical and solution state
Characterize the material under storage and experimental conditions.
State-dependent usability
Treat thermal behavior, solubility, and stability as conditional measurements; no universal numerical values are assumed.
- What phase, melting or decomposition behavior, and storage stability are measured for this specific form of meglitinide? measurement
- At the proposed solvent, pH, temperature, and concentration, does meglitinide remain dissolved and chemically intact for the required duration? measurement
Meglitinide biological evidence Evaluate biological claims made about the individual compound and distinguish them from claims about the glinide class.
Tested compound attribution
Connect every activity claim to a clearly identified test article.
Direct meglitinide evidence
Use proposed insulin-secretagogue and potassium-channel effects as research questions until direct compound-specific evidence is established.
- Which primary experiments tested the individual meglitinide compound, with sufficient identifiers to exclude repaglinide or another glinide? provenance
- What direct evidence establishes effects on ATP-sensitive potassium channels, receptor binding, or insulin secretion for that test article? measurement
Assay context and transfer
Bound what a biological result supports beyond its original experimental setting.
Activity context
Assess potency and functional effects together with exposure, biological system, and controls rather than treating a class description as a compound measurement.
- What species, cell system, glucose condition, dissolved concentration, exposure duration, and controls underpin the reported response? measurement
- Which conclusions remain limited to the assay, and which have direct evidence in intact organisms or humans? boundary
Meglitinide handling and use Determine which actions are supported for the identified compound and material.
Compound-specific hazards
Establish handling requirements using evidence applicable to the actual meglitinide material.
Hazard evidence and gaps
Keep verified classifications, biological hazard evidence, and missing information distinct; an absent classification does not establish absence of hazard.
- Which safety data sheet and jurisdiction-specific GHS classifications match this compound, chemical form, and supplied material? provenance
- What compound-specific evidence supports exposure controls, spill response, disposal requirements, or an occupational exposure limit? action
Permitted use and readiness
Separate the intended action from the evidence and authorization needed to perform it.
Use decision
Evaluate research and medicinal-use claims for the exact compound without inheriting permissions or dosing practices from other meglitinides.
- What authoritative record establishes any research restrictions or medicinal authorization for this exact compound in the relevant jurisdiction and date? provenance
- Does the proposed experiment have adequate identity, purity, stability, biological-evidence, and handling support, or which missing evidence prevents proceeding? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of meglitinide this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of meglitinide this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of meglitinide this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of meglitinide this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Meglitinides are a class of short-acting, non-sulfonylurea insulin-secretagogue drugs that stimulate insulin release from pancreatic beta cells and are used to treat type 2 diabetes.
In scope
- Class identity includes its distinction from the individual compound named meglitinide.
- Class membership includes medicines such as repaglinide and nateglinide.
- Shared pharmacology includes stimulation of pancreatic beta-cell insulin release.
- Class-level information includes therapeutic roles, hypoglycaemia risks and relevant interactions.
- Evidence interpretation distinguishes shared class properties from member-specific indications, warnings and regulatory status.
Out of scope
- The individual parent compound's molecular identity and material properties are outside scope.
- Complete independent substance models for individual class members are outside scope.
- Finished medicinal products, formulations and commercial packaging are outside scope.
- Patient-specific diabetes diagnosis, prescribing and dosing are outside scope.
- Manufacturing processes and laboratory equipment as independently modelled things are outside scope.
Why it exists Filled
Enable an agent to identify the meglitinide drug class and its members, explain their shared pharmacological role and distinguish class-level information from evidence about individual medicines.
Distinguishing features Filled
- The referent is a drug class rather than a single molecular structure.
- Members are short-acting insulin secretagogues that act on pancreatic beta cells.
- The class is distinct from sulfonylureas despite sharing the ability to stimulate insulin release.
- A class designation does not assign the parent compound's molecular identifiers to every member.
- Evidence about one member does not automatically establish the same indication, interaction or regulatory status for all members.
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust a meglitinide-class medicine for a specific person.
- Advise anyone to obtain or use glucose-lowering drugs without a prescription.
- Help use a glucose-lowering drug to harm someone.
- Present the parent compound as an approved medicine where it is not.
Only with a human decision
- Starting, stopping or changing any glucose-lowering treatment for a patient.
May
- Explain what meglitinide and the meglitinide drug class are, citing pharmacology sources.
- Report approved products in the class, their indications and warnings from official labelling.
Moral aspects Filled
- Glucose-lowering drugs can cause dangerous low blood sugar.
- People with diabetes rely on accurate drug information.
Who is affected
- Patients with diabetes
- Prescribers and pharmacists
- Carers
Owners Filled
Steward
The prescriber and the pharmacist for each patient; medicines regulators authorize products.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q79529 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.meglitinide
- Wikidata: Q412926 (https://www.wikidata.org/wiki/Q412926)
Direct properties required Filled
- Registry referent resolution: individual compound confirmed | drug class confirmed | unresolved
- Structure and identifier agreement: Registry source linked to verified structure, PubChem CID, CAS number, and EC number where established
- Chemical form: parent compound | specified salt | specified solvate or hydrate | mixture | unresolved
- Meglitinide content and impurity profile: mass fraction %, chromatographic area %, or molar concentration, with method and uncertainty
- Phase and thermal behavior: phase at stated temperature and pressure; melting or decomposition interval in °C
- Solubility and solution condition: mg/mL or mol/L with solvent, pH, temperature, equilibration time, and chemical form
- Compound-specific biological activity: assay endpoint, concentration-response, and IC50 or EC50 in mol/L where applicable
- Handling and use evidence: supported | restricted | unresolved, separately for each proposed action and jurisdiction
Recognition required Filled
- Identified by product label, active ingredient name and batch records rather than appearance.
Capabilities and actions required Filled
- Resolve whether a supplied record identifies the compound or the drug class.
- Compare a material's analytical identity with a verified meglitinide reference.
- Assess whether purity, chemical form, and solution condition support a proposed experiment.
- Separate compound-specific biological evidence from evidence about other glinides.
- Identify missing handling, stability, or authorization evidence before approving a proposed use.
Hazards and failure modes required Filled
- Low blood sugar, especially if a meal is skipped.
- Interactions with other medicines.
- Misuse to cause harm.
Standards and interfaces required Filled
- The WHO Collaborating Centre for Drug Statistics Methodology classifies the meglitinide medicines repaglinide and nateglinide within ATC group A10BX for other blood glucose lowering drugs excluding insulins.
- The European Parliament and Council's Directive 2001/83/EC governs human medicinal products containing meglitinide medicines within its scope.
Context of use required Filled
- Meglitinides are encountered in type 2 diabetes care as oral medicines that stimulate pancreatic insulin release.
- The class is also studied in pharmacology to investigate insulin secretion and glucose regulation.
- The parent compound and individual medicines in the class require separate identification because their evidence and approved uses differ.
Sources Filled
- Wikidata item Q412926: meglitinide - identity and sense of the item
- Wikipedia: Meglitinide - general description of the item
Open questions
- Does vr.tr.meglitinide refer to the individual compound or the drug class, and does an existing Vercy model already own that referent?
- Which structure, CAS number, EC number, and synonyms are verified for the intended registry referent?
- Which primary studies establish biological activity for the individual compound rather than for related glinides?
- What measured purity, solubility, thermal, and stability data exist for identifiable meglitinide material and chemical forms?
- What compound-specific hazard classifications, exposure limits, and regulatory or medicinal-use records can be verified?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q412926/spec.json